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A B S T R A C T
The search for novel targeted inhibitors active on glioblastoma multiforme is crucial to develop new treatments
for this unmet clinical need. Herein, we report the results from a screening campaign against glioma cell lines
using a proprietary library of 100 structurally-related pyrazolopyrimidines. Data analysis identified a family of
compounds featuring a 2-amino-1,3-benzoxazole moiety (eCF309 to eCF334) for their antiproliferative prop-
erties in the nM range. These results were validated in patient-derived glioma cells. Available kinase inhibition
profile pointed to blockade of the PI3K/mTOR pathway as being responsible for the potent activity of the hits.
Combination studies demonstrated synergistic activity by inhibiting both PI3Ks and mTOR with selective in-
hibitors. Based on the structure activity relationships identified in this study, five new derivatives were syn-
thesized and tested, which exhibited potent activity against glioma cells but not superior to the dual PI3K/mTOR
inhibitor and lead compound of the screening eCF324.
1. Introduction
Glioblastoma multiforme (GBM) is the most common and aggressive
cancer that begins within the brain. It accounts for 45% of all primary
brain tumors with an incidence of four to five per 100,000 adults per
year in Europe.1 Without treatment, the median overall survival fol-
lowing diagnosis is merely 3 months, while with the best available
surgical and adjuvant therapies (chemo and radiotherapy) can only be
extended to 14–15 months.2 Despite a plethora of clinical trials across
the world, GBM remains an unmet medical need, as novel strategies
have failed to show an improvement over the standard of care, temo-
zolomide (TMZ), an alkylating agent approved in the late 90s.3
Phenotypic screening campaigns are the major source of first-in-
class drugs that eventually reach the clinic.4 In contrast to target-centric
strategies, these cell-based compound screens survey changes in the cell
phenotype, thereby embracing the complexity of the cell as a whole.
This is especially important in cancer since redundancy, compensatory
mechanisms, pathway cross-talks and plasticity are common and hardly
predictable. In particular, GBM shows high heterogeneity at the mole-
cular, genetic and epigenetic levels,5 which makes essential the use of
models that recapitulate the disease, including the selection of various
glioma cell types. Even if serendipitous, the discovery of hits through
phenotypic screening on appropriate cell models can improve the odds
of clinical translatability. For example, a phenotypic screening
repurposing campaign in patient-derived glioma cells showed that
combination of disulfiram (a drug used to treat alcoholism) and copper
mediated promising activity and re-sensitization to TMZ, especially in
glioma stem cell-like cells.6 This combination is currently in clinical
phase.7
Phenotypic screening is typically followed by a target engagement/
deconvolution step to identify the target/s and mechanism of action.8,9
However, the appropriate target ID strategy must be optimized for each
individual biological target and preclinical drug, representing a tech-
nically challenging step. In fact, some drug candidates reach regulatory
approval without the actual knowledge of their action mechanism,10
which can potentially hinder further clinical development activities due
to the lack of appropriate biomarkers.
Using a pragmatic strategy that combines ligand-based drug design
and phenotypic screening of selected cancer cell lines, our lab has
generated several series of focused small molecule compounds featuring
either a 4-amino or 6-methylamino pyrazolo[3,4-d]pyrimidine core (see
Fig. 1) and discover potent “phenotypic” hits and lead compounds
displaying a diversity of anticancer properties, including cell cycle ar-
rest, pro-apoptotic and anti-migrative activities.11–13 Since these scaf-
folds are typically found in kinase inhibitors, kinome profiling of these
hits and leads enabled fast elucidation of their target profile and the
generation of structure activity relationship (SAR) to support sub-
sequent optimization activities. Such campaigns resulted, for example,
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in the discovery of the potent SRC/nonABL kinase inhibitor eCF506,11
the selective mTOR inhibitor eCF309,12 or the potent FLT3/AXL/RET
inhibitor eSM156.13
2. Results and discussion
A phenotypic screening campaign was performed using our in-house
developed library14,15 in search for small molecule inhibitors that could
affect glioma cell proliferation. As shown in Fig. 1, the library used in
the screening represents a highly-focused chemical-diversity space (see
complete structural information in the Table 1 of the Suppl. Data).
Importantly, this space is rich in bioactive compounds that have been
shown to target a variety of protein, lipid and atypical kinases,11–17 thus
improving the chances of finding active hits against glioma cells while
facilitating the interpretation of potential SAR.
The antiproliferative activity of a total of 100 compounds was tested
against U87 and T98 glioma cell lines, using TMZ3 and the Topoi-
somerase I inhibitor SN-3818 as positive controls. Cells were treated
with the library members for 5 d at three different concentrations (3, 30
and 300 µM) and cell viability determined using the PrestoBlue reagent.
Half-maximal effective concentration (EC50) values were calculated
from the corresponding dose-response curves and plotted in Fig. 2a as a
heatmap to facilitate data analysis, with black meaning no activity and
dark to light green to yellow transitions indicating decreasing EC50
values (=increasing potencies). Table 1 of the Suppl. Data contains the
corresponding EC50 values ± SEM. Whereas compounds based on
scaffold 2 (third column, Fig. 2a) were found to be more active in
general than those from scaffold 1 (first and second columns, Fig. 2a),
the highest activities were exhibited by a particular family of com-
pounds from the eCF series (eCF309 to eCF334). Structurally speaking,
these potent compounds presented a 2-amino-1,3-benzoxazole moiety
at the C3 position of the ring, a group that is also found in the mTOR
inhibitor sapanisertib (a.k.a. INK128), a drug candidate currently in
clinical development.19
To confirm the results, U87 and T98 cell viability assays were re-
peated for the most potent hits (eCF309, eCF311, eCF312, eCF324,
eCF325, eCF333 and eCF334, all of which feature a 2-amino-1,3-
benzoxazole moiety at the C3 position) using a 7-point half-log do-
se–response study (1 to 1,000 nM). INK128 and SN-38 were used as
positive controls. Resulting curves are shown in Fig. 2b and c. eCF333
and eCF334 (pure enantiomers of eCF325) presented identical dose
response curves to that of eCF325, and thus their data were not
included for clarity. As shown in Fig. 2b and c, eCF324 was the most
potent compound in both cell lines, displaying EC50 values of 13 and
10 nM in U87 and T98 cells, respectively; values that were superior to
those of the positive controls INK128 and SN-38. Of note,> 200-fold
activity gap was observed between lead compounds eCF324 and
eCF311; the latter presenting a methyl-1-3-dioxolane group at N1 in-
stead of a methylcyclopentane. The rest of the hits exhibited EC50 va-
lues in the range of 100–150 nM. Structurally, these derivatives differed
in the size of the alkyl group of the N1 position and the presence or
absence of an oxygen atom in that moiety (see Suppl. Data). None of
them exhibited superior potency than eCF324, indicating that the most
lipophilic cyclopentylmethyl group found in this compound is optimal
for activity.
In order to correlate the antiproliferative activities of the pheno-
typic hits with potential target/s, we took advantage of kinase profiling
data previously obtained for these compounds.12 As shown in the Suppl.
Data, all the hits display high inhibitory activity for mTOR kinase, being
eCF309 the most selective (IC50 (mTOR) = 15 nM; IC50
(PI3Kα) = 981 nM) and eCF324 the most potent (IC50
(mTOR) = 1.8 nM; IC50 (PI3Kα) = 3.5 nM). The antiproliferative po-
tency exhibited by the selective mTOR inhibitor eCF309 strongly sup-
ports the role of mTOR inhibition in the antiproliferative properties of
the hits. On the other hand, the superior anti-glioma activity of eCF324
suggests that its polypharmacological properties are beneficial for in-
hibiting glioma cell proliferation. To study the possible role of PI3K
inhibition, additional cell viability studies were performed in U87 and
T98 cells with the selective pan-PI3K inhibitor pictilisib (a.k.a.
GDC094120). As shown in Fig. 3, although both eCF309 and eCF324
display superior activity than the pan-PI3K inhibitor GDC0941, this
selective inhibitor exhibits sub-µM activity against T98 (equivalent to
that of eCF309) and low µM activity in U87 cells.
Next, to test whether dual PI3K/mTOR inhibition could provide a
therapeutic advantage to target glioma cells, cell viability studies were
performed in U87 and T98 cells by combining eCF309 with the pan-
PI3K inhibitor GDC0941 at a series of concentrations. Synergy scores
for these combinations are presented in Fig. 4, with the red areas re-
presenting synergy and the green ones antagonism. Notably, strong
synergistic activity was observed in most combinations, with maximum
synergy found at 100 nM of eCF309 and 300 nM of GDC0941 in T98
cells. Since both compounds are known to be selective inhibitors of
mTOR12 and PI3K,20 respectively, this study indicates that concurrent
inhibition of mTOR and PI3Ks potentiate an antiproliferative effect in
Fig. 1. Chemical diversity and historic evolution of the pyrazolopyrimidines tested in this work. Library size = 100 compounds.
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these two glioma cell lines. Combination doses for maximum synergy
differed between U87 and T98 cells, suggesting different expression/
activities of these oncogenic drivers in each cell line.
Combination experiments were also performed with eCF324 and
GDC0941, which also found synergistic activities (see Suppl. Data).
This may indicate that the inherent inhibitory properties of eCF324 on
mTOR and PI3K are not optimally balanced to reach maximal sy-
nergistic anticancer activity and additional PI3K inhibition can promote
further the antiproliferative effect mediated by this agent. Nevertheless,
this possible interpretation needs to be taken with caution due to the
known promiscuity of eCF32412; additional off-target effects may be at
play in this case.
To corroborate the results in a more clinically-relevant model, a
patient-derived GBM cell line, G317, was tested next. Fig. 5 shows the
inhibition of cell growth by the most potent hits in this cell line. GI50
values (50% of growth inhibition) in G317 are represented in Table S1
(Suppl. Data). The choice of obtaining GI50 values instead of EC50 was
made to determine if the compounds mediate cell growth arrest (cell
viability values over the basal line) or cell death (cell viability values
below the basal line). In agreement with previous results, compound
eCF324 exhibited the greatest potency with a GI50 valued of 7.2 nM,
similar to INK128 but higher than the Topoisomerase-I inhibitor SN-38
and the pan-PI3K inhibitor GDC0941. Data from eCF333 and eCF334
showed identical dose response curves to eCF325 and, therefore, were
not shown in Fig. 5 for clarity. Of note, all compounds induced cell
death, which contrast with the antiproliferative mode of action pre-
viously observed in breast and prostate cancer cells for these com-
pounds.12 Notably, the selective mTOR inhibitor eCF309 showed very
potent activity in the patient derived cells, with a GI50 value of 65 nM,
further evidence of the central role of mTOR in promoting cell growth
and survival in GBM.23
To test the compounds under conditions that better represent the
tumour microenvironment, G317 cells were cultured in 3D and pre-
formed spheroids treated with eCF309, eCF324 and the positive con-
trols at a range of concentrations (0.01–10 µM) for 8 days. As shown in
Figure 6, inhibitors induced a dose dependent reduction of G317
spheroid size, with eCF324 and INK128 exhibiting the most potent
antiproliferative activities.
Preliminary assessment of the safety profile of the hits was per-
formed in two noncancerous cell lines: human brain vascular pericytes
(HBVP) and mouse brain endothelial cells (bEnd3). Cell viability studies
(see Suppl. Data) showed that the hits of the screening affected normal
cell proliferation at concentrations above 3 µM, two to three orders of
magnitude higher dose than that required to reduce proliferation of
glioma cells.
Based on the lead compounds identified in the screening, five new
derivatives were designed and synthesised to bring together the best
structural features observed from the SAR of the screen. Compound
eDB001 was designed to incorporate the 2-amino-1,3-benzoxazole
group found at C3 of eCF324 into scaffold 2. The other four com-
pounds incorporated the cyclopentylmethyl moiety found at the N1
position of eCF324 and either an azaindole or indazole group at C3 in
each scaffold to explore SAR further. eDB002 and eDB003 displayed
Fig. 2. (a) Heatmaps of EC50 values of the 100 final compounds tested. Data represents mean values of three independent experiments in triplicates. (b and c) Dose
response curves of most potent hits on (b) U87 and (c) T98 cells. Cells were treated with each inhibitor at concentrations ranging from 1 to 30,000 nM and PrestoBlue
assay used at day 5 to detect viability. Data are means ± SEM of 3 independent experiments in triplicates.
Fig. 3. EC50 values for eCF324, eCF309, positive controls INK128 and SN-38
and pan-PI3K inhibitor GDC0941 on glioma U87 and T98 cell lines. Cells were
treated with each inhibitor at concentrations ranging from 1 to 1,000 nM and
PrestoBlue assay used at day 5 to detect viability. Data are mean ± SEM of
three independent experiments in triplicates, *P < 0.05, **P < 0.01,
***P < 0.001 compared to eCF324.
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the same group than eSM145, also found in KW-2449,21 a potent multi-
kinase inhibitor of FLT3, ABL, and related kinases. An indazole group
was used for eDB004 and eDB005 to mimic the structural properties of
the selective pan-PI3K inhibitor GDC0941. As shown in Fig. 7, eDB001
and eDB002 displayed high activity in both cell lines, although their
EC50 values did not reach the potency of eCF324. Given the results of
the new derivatives, future optimization strategies should focus on
scaffold 1 and modify the 2-amino-1,3-benzoxazole moiety at C3 and
the lipophilic group at N1 to enhance activity.
3. Materials and methods
3.1. General
Commercially available chemicals and anhydrous solvents were
purchased from a range of suppliers, including: Acros Organics, Alfa
Aesar, Fisher Scientific, Fluorochem, Matrix Scientific, Sigma Aldrich
and VWR International. Cell culture plasticware was obtained from
Greiner or Corning/Costar.
3.2. Cell culture
U87 and T98 cells (ATCC) were cultured in DMEM (Gibco), sup-
plemented with 10% (v/v) FBS (Gibco) and 2 mM L-Glutamine (Gibco)
in a standard incubator (95% humidity, 5% CO2), and subcultured
twice per week through trypsinization. G317 patient-derived glioma
Fig. 4. Synergy scores for the combinations of eCF309 and GDC0941 on (a)
U87 and (b) T98 cells. Cells were treated with combinations of 1000, 300, 100,
30, 10, 0 nM of eCF309 and/or 10,000, 3000, 1000, 300, 100, 30, 10, 3, 0 nM of
GDC0941 during 5 days and PrestoBlue assay was used to detect viability. The
most synergistic area is highlighted (white line). Data are ZIP synergy scores of
means of three independent experiments.
Fig. 5. Dose response curves of most potent hits on the patient-derived cell line
G317. Cells were treated with each inhibitor at concentrations ranging from 1
to 10,000 nM and PrestoBlue assay used at day 5 to detect viability. Cell growth
was related to DMSO treatment (100%) and before drug treatment (0%), and
GI50 values were extrapolated from the sigmoidal dose–response curve. Data
are means ± SEM of 3 independent experiments in triplicates.
Fig. 6. (a) Images of G317 spheroids on day 10. Spheroids were treated with
10 μM of each inhibitor during 8 days, images were acquired using
ImageXpress. Scale bar = 100 μm. (b) Area of G317 patient derived spheroids
at day 10. Spheroid area was calculated with a custom pipeline on CellProfiler.
Data are mean ± SEM of 6 independent spheroids from two different cultures,
***P < 0.001, **P < 0.01 compared to DMSO controls (two-way ANOVA,
Tukey post hoc test).
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cells were established by the Glioma Cellular Genetics Resource
(gcgr.org.uk) funded by Cancer Research UK. Ethics approval for use of
patient-derived cells and early access confirmation to reagents from the
Glioma Cellular Genetics Resource assured that all ethical issues ac-
cording to UK legislation are fulfilled. G317 were cultured in DMEM/
HAMS-F12 (Sigma) supplemented with 1.5 g L−1 D-(+)-Glucose
(Sigma), MEM non-essential aminoacids (Gibco), 0.015% (w/v)
Penicillin-Streptomycin (Gibco), 0.012% (w/v) BSA (Gibco), 0.1 mM β-
mercaptoethanol (Gibco), B27 (Gibco) and N2 supplements (Gibco).
Cells were detached using accutase solution (Sigma) and subcultured
once per week. Before adding to the cells, medium was supplemented
with 10 ng ml−1 mouse EGF (Preprotech), 10 ng ml−1 human FGF
(Preprotech), and 1 µg ml−1 Laminin (Sigma).
3.3. Cell viability assay
1 × 103 U87 cells/well, 5 × 102 T98 cells/well, 1 × 104 G317
cells/well, 1 × 104 HBVP cells/well and 1 × 104 bEnd3 cells/well were
seeded in 96-well plates. After 48 h in culture, cells were treated with
the inhibitors for 5 d. For GI50 determination, the viability of a triplicate
sample of each experiment before treatment was measured with the
PrestoBlue Reagent (Invitrogen), to establish a basepoint 0% of growth.
After 5 d, the viability was measured with PrestoBlue and related to 0%
(indicating total cell death for EC50 determination or growth inhibition
for GI50) and 100% viability (cells in the absence of drug). ZIP Synergy
scores were obtained with Synergy finder.22 Viability percentage, EC50
and GI50 values were obtained using GraphPad Prism version 8.0.0 for
Windows, GraphPad Software, San Diego, California USA, www.
graphpad.com.
3.4. Spheroids assay
4 × 103 G317 cells were seeded in an ultra-low attachment round
bottom 96-well plate, centrifuged at 1000g, 4 °C for 10 min and allowed
to form spheroids for 2 days. Spheroids were then incubated with the
inhibitors at 4 concentrations ranging from 10 nM to 10 µM. Spheroids
were imaged at day 10 using ImageXpress (Molecular Devices LLC) and
processed with ImageJ.25 Spheroid area was calculated with a custom
pipeline on CellProfiler.26
4. Conclusions
A series of structurally related pyrazolopyrimidine derivatives have
been identified as potent inhibitors of glioma cell proliferation by a cell-
based screening of a focused library of 100 pyrazolopyrimidines. The
most potent hits displayed sub-micromolar activity against U87 and
T98 glioma cell lines. The hits belonged to a group of compounds
known to target mTOR and/or PI3Ks, including the selective mTOR
inhibitor eCF309 and the dual PI3K/mTOR inhibitor eCF324. Based on
SAR identified in this study, new derivatives were designed, which
exhibited potent activities against glioma cells but not superior to the
lead compound eCF324. Synergy studies with the commercially-avail-
able selective pan-PI3K inhibitor GDC0941 provided evidence of the
synergistic effect of concurrently inhibiting mTOR and PI3Ks in glioma
cell growth. The most potent hits were also validated in a patient-de-
rived glioma cell model in 2D and 3D. This work further supports the
search for inhibitors that can target PI3Ks and/or mTOR kinases23,24 to
fight GBM.
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